☰

Max C. Tsai, Ph.D. - Publications

Affiliations: 
2003 Ohio State University, Columbus, Columbus, OH 
Area:
Pharmacy, Oncology
Tree Info Grants Similar researchers PubMed Report error

7/34 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Au JL, Guo P, Gao Y, Lu Z, Wientjes MG, Tsai M, Wientjes MG. Multiscale tumor spatiokinetic model for intraperitoneal therapy. The Aaps Journal. 16: 424-39. PMID 24570339 DOI: 10.1208/S12248-014-9574-Y  0.64
2014 Lu Z, Tsai M, Wang J, Cole DJ, Wientjes MG, Au JLS. Activity of drug-loaded tumor-penetrating microparticles in peritoneal pancreatic tumors Current Cancer Drug Targets. 14: 70-78. PMID 24200079 DOI: 10.2174/15680096113136660110  0.557
2013 Tsai M, Lu Z, Wientjes MG, Au JL. Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. Journal of Controlled Release : Official Journal of the Controlled Release Society. 172: 737-44. PMID 24056144 DOI: 10.1016/J.Jconrel.2013.09.011  0.63
2011 Gao Y, Guo P, Lu Z, Tsai M, Wientjes MG, Au JL. Abstract 5453: Drug transport in peritoneal tumors during intraperitoneal therapy – evaluation by computational model Cancer Research. 71: 5453-5453. DOI: 10.1158/1538-7445.Am2011-5453  0.654
2008 Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. The Journal of Pharmacology and Experimental Therapeutics. 327: 673-82. PMID 18780831 DOI: 10.1124/Jpet.108.140095  0.693
2007 Tsai M, Lu Z, Wang J, Yeh TK, Wientjes MG, Au JL. Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharmaceutical Research. 24: 1691-701. PMID 17447121 DOI: 10.1007/S11095-007-9298-0  0.637
2004 Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7677-84. PMID 15570001 DOI: 10.1158/1078-0432.Ccr-04-1443  0.598
Low-probability matches (unlikely to be authored by this person)
2023 Luffer-Atlas D, Wilbraham D, Posada MM, Landry J, Tsai M, Pearlman EM. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates. Journal of Clinical Pharmacology. PMID 37566903 DOI: 10.1002/jcph.2328  0.246
2019 Wilbraham D, Berg PH, Tsai M, Liffick E, Loo LS, Doty EG, Sellers E. Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study. Journal of Clinical Pharmacology. PMID 31745991 DOI: 10.1002/Jcph.1543  0.246
2020 Tsai M, Case M, Ardayfio P, Hochstetler H, Wilbraham D. Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol. Clinical Pharmacology in Drug Development. PMID 31950732 DOI: 10.1002/cpdd.768  0.182
2013 Naik H, Tsai MC, Fiedler-Kelly J, Qiu P, Vakilynejad M. A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis. Plos One. 8: e66422. PMID 23840463 DOI: 10.1371/Journal.Pone.0066422  0.168
2023 Yin W, Facius A, Wagner T, Tsai M, Asgharnejad M, Lahu G, Vakilynejad M. Population pharmacokinetics, enzyme occupancy, and 24S-hydroxycholesterol modeling of soticlestat, a novel cholesterol 24-hydroxylase inhibitor, in healthy adults. Clinical and Translational Science. PMID 37212649 DOI: 10.1111/cts.13517  0.155
2020 Wilbraham D, Biglan KM, Svensson KA, Tsai M, Kielbasa W. Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator (D1PAM), in Healthy Subjects. Clinical Pharmacology in Drug Development. PMID 33029934 DOI: 10.1002/cpdd.874  0.148
2021 Tsai M, Nery ESM, Kerr L, Khanna R, Komori M, Dennehy EB, Wilbraham D, Winner P. Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine. Clinical Pharmacokinetics. PMID 33565026 DOI: 10.1007/s40262-020-00966-z  0.126
2015 Tsai MC, Wu J, Kupfer S, Vakilynejad M. Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients with Stage 2 Hypertension. Journal of Clinical Pharmacology. PMID 26632101 DOI: 10.1002/jcph.684  0.124
2021 Wilbraham D, Biglan KM, Svensson KA, Tsai M, Pugh M, Ardayfio P, Kielbasa W. Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor-Positive Allosteric Modulator, in Patients With Parkinson Disease. Clinical Pharmacology in Drug Development. PMID 34664427 DOI: 10.1002/cpdd.1039  0.111
2018 Gilleen J, Farah Y, Davison C, Kerins S, Valdearenas L, Uz T, Lahu G, Tsai M, Ogrinc F, Reichenberg A, Williams SC, Mehta MA, Shergill SS. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients. Psychopharmacology. PMID 30536081 DOI: 10.1007/s00213-018-5134-y  0.103
2012 Naik H, Tsai M, Qiu P, Vakilynejad M. A Population Pharmacokinetic (Pk)- Pharmacodynamic (Pd) Analysis Of Peginesatide India Lysis Patients With Chronic Kidney Disease Kidney Research and Clinical Practice. 31. DOI: 10.1016/J.Krcp.2012.04.496  0.098
2019 Blokland A, Van Duinen MA, Sambeth A, Heckman PRA, Tsai M, Lahu G, Uz T, Prickaerts J. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study. Neurobiology of Aging. 77: 37-43. PMID 30776650 DOI: 10.1016/j.neurobiolaging.2019.01.014  0.098
2017 Van Duinen MA, Sambeth A, Heckman PRA, Smit S, Tsai M, Lahu G, Uz T, Blokland A, Prickaerts J. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. Neuropharmacology. 131: 31-38. PMID 29241652 DOI: 10.1016/j.neuropharm.2017.12.019  0.095
2018 Takano A, Uz T, Garcia-Segovia J, Tsai M, Lahu G, Amini N, Nakao R, Jia Z, Halldin C. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[C]Rolipram. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 29441434 DOI: 10.1007/S11307-018-1168-0  0.09
2016 Webb NJ, Wells T, Tsai M, Zhao Z, Juhasz A, Dudkowski C. Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults. European Journal of Clinical Pharmacology. PMID 26725367 DOI: 10.1007/s00228-015-1987-8  0.075
2016 Takano A, Stenkrona P, Stepanov V, Amini N, Martinsson S, Tsai M, Goldsmith P, Xie J, Wu J, Uz T, Halldin C, Macek TA. A human [(11)C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor. Neuroimage. PMID 27423256 DOI: 10.1016/J.Neuroimage.2016.06.047  0.073
2017 Goldsmith P, Affinito J, McCue M, Tsai M, Roepcke S, Xie J, Gertsik L, Macek TA. A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events. Drugs in R&D. PMID 29103081 DOI: 10.1007/S40268-017-0214-8  0.067
2020 KOMORI M, MIMURA H, TSAI M, OZEKI A, TAKAICHI G, WILBRAHAM D. Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects Rinsho Yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 51: 119-127. DOI: 10.3999/jscpt.51.119  0.067
2020 Pearlman EM, Wilbraham D, Dennehy EB, Berg PH, Tsai M, Doty EG, Kay GG. Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls. Human Psychopharmacology. e2732. PMID 32449213 DOI: 10.1002/hup.2732  0.066
2012 Tsai M, Wu JT, Gunawardhana L, Naik H. The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. International Journal of Clinical Pharmacology and Therapeutics. 50: 331-7. PMID 22541837 DOI: 10.5414/CP201648  0.063
2019 Biglan K, Svensson KA, Wilbraham D, Tsai M, Kielbasa W. P1-057: A MULTIPLE ASCENDING-DOSE STUDY OF THE PHARMACOKINETICS AND SAFETY OF LY3154207, A CENTRALLY-ACTING DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (D1 PAM), IN HEALTHY SUBJECTS Alzheimer's & Dementia. 15: P254-P255. DOI: 10.1016/j.jalz.2019.06.082  0.057
2016 Dudkowski C, Tsai M, Liu J, Zhao Z, Schmidt E, Xie J. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus. European Journal of Clinical Pharmacology. PMID 27999883 DOI: 10.1007/s00228-016-2175-1  0.054
2020 Gilleen J, Nottage J, Yakub F, Kerins S, Valdearenas L, Uz T, Lahu G, Tsai M, Ogrinc F, Williams SC, Ffytche D, Mehta MA, Shergill SS. The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial. Journal of Psychopharmacology (Oxford, England). 269881120946300. PMID 32854568 DOI: 10.1177/0269881120946300  0.047
2016 Tsai M, Chrones L, Xie J, Gevorkyan H, Macek TA. A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. Psychopharmacology. PMID 27572830 DOI: 10.1007/S00213-016-4412-9  0.044
2015 Takano A, Stenkrona P, Stepanov V, Amini N, Martinsson S, Tsai M, Goldsmith P, Wu J, Xie J, Uz T, Macek T, Halldin C. P.1.i.028 Brain phosphodiesterase 10A occupancy measured by PET after oral administration of TAK-063, a newly developed phosphodiesterase 10A inhibitor, in human volunteers European Neuropsychopharmacology. 25: S316. DOI: 10.1016/S0924-977X(15)30387-4  0.031
2015 Takano A, Stepanov V, Stenkrona P, Amini N, Martinsson S, Tsai M, Goldsmith P, Wu J, Xie J, Uz T, Macek T, Halldin C. P.1.i.027 Quantitative analysis and test-retest reproducibility of a new phosphodiesterase 10A PET radioligand [11C]T-773 in human brain European Neuropsychopharmacology. 25: S315. DOI: 10.1016/S0924-977X(15)30386-2  0.013
2017 Van Duinen M, Sambeth A, Heckman P, Tsai M, Lahu G, Uz T, Blokland A, Prickaerts J. The PDE4-inhibitor roflumilast improves memory: findings from a translational perspective European Neuropsychopharmacology. 27: S1024-S1025. DOI: 10.1016/S0924-977X(17)31794-7  0.01
Hide low-probability matches.